1. Home
  2. CERO vs SGLY Comparison

CERO vs SGLY Comparison

Compare CERO & SGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CERO
  • SGLY
  • Stock Information
  • Founded
  • CERO 2017
  • SGLY 2001
  • Country
  • CERO United States
  • SGLY United States
  • Employees
  • CERO 8
  • SGLY N/A
  • Industry
  • CERO
  • SGLY
  • Sector
  • CERO
  • SGLY
  • Exchange
  • CERO Nasdaq
  • SGLY Nasdaq
  • Market Cap
  • CERO 3.7M
  • SGLY 3.7M
  • IPO Year
  • CERO N/A
  • SGLY 2008
  • Fundamental
  • Price
  • CERO $0.45
  • SGLY $0.92
  • Analyst Decision
  • CERO Buy
  • SGLY
  • Analyst Count
  • CERO 2
  • SGLY 0
  • Target Price
  • CERO $3.00
  • SGLY N/A
  • AVG Volume (30 Days)
  • CERO 993.4K
  • SGLY 457.6K
  • Earning Date
  • CERO 05-15-2025
  • SGLY 05-15-2025
  • Dividend Yield
  • CERO N/A
  • SGLY N/A
  • EPS Growth
  • CERO N/A
  • SGLY N/A
  • EPS
  • CERO N/A
  • SGLY N/A
  • Revenue
  • CERO N/A
  • SGLY $2,172,036.00
  • Revenue This Year
  • CERO N/A
  • SGLY N/A
  • Revenue Next Year
  • CERO N/A
  • SGLY N/A
  • P/E Ratio
  • CERO N/A
  • SGLY N/A
  • Revenue Growth
  • CERO N/A
  • SGLY N/A
  • 52 Week Low
  • CERO $0.40
  • SGLY $0.54
  • 52 Week High
  • CERO $102.00
  • SGLY $7.65
  • Technical
  • Relative Strength Index (RSI)
  • CERO 35.19
  • SGLY 50.30
  • Support Level
  • CERO $0.42
  • SGLY $0.82
  • Resistance Level
  • CERO $0.50
  • SGLY $1.03
  • Average True Range (ATR)
  • CERO 0.05
  • SGLY 0.14
  • MACD
  • CERO 0.00
  • SGLY -0.01
  • Stochastic Oscillator
  • CERO 24.77
  • SGLY 15.08

About CERO CERo Therapeutics Holdings Inc. Common Stock

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

About SGLY Singularity Future Technology Ltd.

Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.

Share on Social Networks: